Mutation of BCL-2 family proteins in cancer

Apoptosis

Volumn 3, Issue 2, 1998, Pages 75-82

  Packham, G ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Apoptosis; BCL 2; BCL X; Cancer

Indexed keywords

EID: 0009975004     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009688706783     Document Type: Article

References (48)

1. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3: 614-620.
2. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-776.
3. Craig RW. The bcl-2 gene family. Semin Cancer Biol 1995; 6: 35-43.
4. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 1995; 13: 513-543.
5. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the bcl2 family and cell death. Blood 1996; 88: 386-401.
6. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerisation with Bax. Nature 1994; 369: 321-323.
7. Zha H, Aime-Sempe G, Sato T, Reed JC. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 1996; 271: 7440-7444.
8. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerises in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
9. L, an inhibitor of programmed cell death. Nature 1996; 381: 335-341.
10. Antonsson B, Conti F, Ciavatti A, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997; 277: 370-372.
11. L forms an ion channel in synthetic lipid membranes. Nature 1997; 385: 353-357.
12. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC. Channel formation by anti-apoptotic protein, Bcl-2. Proc Natl Acad Sci USA 1997; 94: 5113-5118.
13. Baffy G, Miyashita T, Williamson JR, Reed JC. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem 1993; 268: 6511-6519.
14. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirements for dATP and cytochrome c. Cell 1996; 86: 147-157.
15. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.
16. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
17. Susin SA, Zanzami N, Castedo M, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996; 184: 1331-1342
18. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homolgous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413
19. Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on regulation of the mitochondrial permeability transition pore: a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerget Biomembr 1994; 26: 509-517.
20. Zoratti M, Szabo I. Electrophysiology of the inner mitochondrial membrane. J Bioenerget Biomembr 1996; 26: 543-553.
21. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.
22. Spector MS, Desnoyers S, Hoeppner DJ, Hengartner MO. Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature 1997; 385: 653-656.
23. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death. Science 1997; 275: 1122-1126.
24. Wu D, Wallen HD, Nunez G. Interaction and regulation of subcellular localisation of CED-4 by CED-9. Science 1997; 275: 1126-1129.
25. L during apoptosis. Proc Natl Acad Sci USA 1997; 94: 3668-3672.
26. Crisan D. BCL-2 gene rearrangements in lymphoid malignancies. Clin Lab Med 1996; 16: 23-47.
27. McDonnell TJ, Deane N, Platt FM, et al. bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
28. Adams JM, Cory S. Transgenic models for haemopoietic malignancies. Biochim Biophys Acta 1991; 1072: 9-31.
29. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutations and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988; 7: 123-131.
30. Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphoma. Blood 1992; 79: 229-237.
31. Reed JC, Tanaka S. Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphomas and lymphocytic leukemias: implications for mechanisms of tumor progression. Leukemia Lymphoma 1993; 10: 157-163.
32. Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphological transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996; 88: 3937-3944.
33. L and Bcl-2. EMBO J 1997; 16: 968-977.
34. Huang DCS, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997; 16: 4628-4638.
35. Uhlmann EJ, D'Sa-Eipper C, Subramanian T, Wagner AJ, Hay N, Chinnadurai G. Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Cancer Res 1996; 56: 2506-2509.
36. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996; 56: 2422-2427.
37. L is selectively regulated by haemopoietins and activated in murine haemopoietic malignancies. J Exp Med (Submitted).
38. Tanner M, Tirkonen M, Kallioniemi A, et al. Independent amplification and frequent co-amplification of three nonsytenic regions of the long arm of chromosome 20 in human breast cancer. Cancer Res 1996; 56: 3441-3445.
39. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obrdovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997: 11: 656-659.
40. Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995; 267: 1506-1510.
41. Knudson CM, Tung KSK, Tourtellote WG, Brown GAJ, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995; 270: 96-99.
42. Yin C, Knudson CM, Korsmeyer SJ, van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-640.
43. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-4478.
44. Apte SS, Mattei M-G, Olsen BR. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, Baxδ. Genomics 1995; 26: 592-594.
45. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-969.
46. Chung Y-J, Park S-W, Song J-M, et al. Evidence of genetic progression in human gastric carcinomas with microsatellite instability. Oncogene 1997; 15: 1719-1726.
47. Brimmell M, Mendiola R, Mangion J, Packham G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; (In press).
48. Meijerink JPP, Smetsers TFCM, Sloetjes AW, Linders EHP, Mensink EJBM. Bax mutations in cell lines derived from hematological malignancies. Leukemia 1995; 9: 1828-1832.